As the first oral GLP-1 receptor agonist to demonstrate a significant reduction in cardiovascular events, the SOUL trial established oral semaglutide as an evidence-based therapy that not only improves glycaemic control but also provides meaningful cardiovascular protection for people with type 2 diabetes who are at high cardiovascular risk
Reta is supported by Janoshik third-party testing, with the test report available for researchers, laboratories and procurement buyers to review
However, patients with CKD require careful monitoring, especially if experiencing severe gastrointestinal adverse effects, and should maintain adequate hydration throughout treatment
And its not too late
Formulated in an oral capsule format for laboratory research focused on angiogenesis, tissue remodeling, and cellular signaling
Decreased appetite (6%) A reported 6% and 9% of patients who took 7 mg and 14 mg of Rybelsus experienced reduced appetite